1-磷酸鞘氨醇在免疫性炎症疾病中的研究进展

摘要/Abstract

摘要： 1-磷酸-鞘氨醇（Sphingosine-1-Phosphate,S1P）是在人体内广泛存在的生物活性脂质分子,其作用涉及合成、降解、转运,S1P/1-磷酸鞘氨醇受体（Sphingosine 1-Phosphate Receptors,S1PRs）介导信号通路等多个方面。经过数十年的研发,目前已经用于治疗数种炎症免疫性疾病。本文综述了S1P的基本代谢、作用机制,其在临床自身免疫炎症性疾病与在皮肤病中的应用,以及对其未来应用前景的展望。

关键词: 1-磷酸-鞘氨醇, 1-磷酸鞘氨醇受体, 1-磷酸-鞘氨醇调节剂, 炎症性疾病, 代谢

中图分类号:

R364.5

郭飞英, 苏冬艳, 周强. 1-磷酸鞘氨醇在免疫性炎症疾病中的研究进展[J]. 中华养生保健, 2024, 42(21): 67-71.

参考文献

[1] 靳慧平. 抑制杏仁中央核的S1PR3可缓解CCI小鼠的疼痛及焦虑抑郁样行为[D]. 郑州:郑州大学,2022.
[2] 吕婷婷, 沈磊. 1-磷酸鞘氨醇在炎症性肠病中的研究进展[J]. 临床消化病杂志,2017,29(5):324-327.
[3] 白洁,扈金萍.鞘氨醇-1-磷酸信号通路相关的药物研究进展[J].药学学报,2016,51(12):1822-1828.
[4] PULKOSKI-GROSS M J, OBEID L M. Molecular mechanisms of regulation of sphingosine kinase 1[J]. Biochim Biophys Acta Mol Cell Biol Lipids, 2018,1863(11):1413-1422.
[5] SNIDER A J, ORR G K, OBEID L M.Sphingosine kinase: Role in regulation of bioactive sphingolipid mediators in inflammation[J]. Biochimie, 2010, 92(6):707-715.
[6] 胡元昌. 高血糖激活的S1P-S1PR3信号通路在肝脏缺血再灌注损伤中的作用及机制研究[D]. 南京:南京医科大学,2019.
[7] SPIEGEL S, MACZIS M A, MACEYKA M, et al.New insights into functions of the sphingosine-1-phosphate transporter SPNS2[J]. J Lipid Res, 2019, 60(3):484-489.
[8] CHRISTOFFERSEN C, OBINATA H, KUMARASWAMY S B, et al.Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M[J]. Proc Natl Acad Sci U S A, 2011,108(23):9613-9618.
[9] KIHARA Y, MACEYKA M, SPIEGEL S, et al.Lysophospholipid receptor nomenclature review: IUPHAR Review 8[J]. Br J Pharmacol, 2014,171(15):3575-3594.
[10] PARK E S, CHOI S, SHIN B, et al.Tumor necrosis factor (TNF) receptor-associated factor (TRAF)-interacting protein (TRIP) negatively regulates the TRAF2 ubiquitin-dependent pathway by suppressing the TRAF2-sphingosine 1-phosphate (S1P) interaction[J]. J Biol Chem, 2015, 290(15):9660-9673.
[11] 张婧瑶, 刘卫东, 刘函晔, 等. 1-磷酸鞘氨醇与相关疾病的研究进展[J]. 生理科学进展,2019,50(3):200-204.
[12] SKOURA A, SANCHEZ T, CLAFFEY K, et al.Essential role of sphingosine 1-phosphate receptor 2 in pathological angiogenesis of the mouse retina[J]. J Clin Invest, 2007,117(9):2506-2516.
[13] BIGAUD M, DINCER Z, BOLLBUCK B, et al.Pathophysiological Consequences of a Break in S1P1-Dependent Homeostasis of Vascular Permeability Revealed by S1P1 Competitive Antagonism[J]. PLoS One, 2016,11(12):e0168252.
[14] NIESSEN F, SCHAFFNER F, FURLAN-FREGUIA C, et al.Dendritic cell PAR1-S1P3 signalling couples coagulation and inflammation[J]. Nature, 2008, 452(7187):654-658.
[15] AWOJOODU A O, OGLE M E, SEFCIK L S, et al.Sphingosine 1-phosphate receptor 3 regulates recruitment of anti-inflammatory monocytes to microvessels during implant arteriogenesis[J]. Proc Natl Acad Sci U S A, 2013,110(34):13785-13790.
[16] GUERRERO M, URBANO M, VELAPARTHI S, et al.Identification of a Novel Agonist of the Sphingosine 1-phosphate Receptor 4 (S1P4)[J]. 2010.
[17] GOLFIER S, KONDO S, SCHULZE T, et al.Shaping of terminal megakaryocyte differentiation and proplatelet development by sphingosine-1-phosphate receptor S1P4[J]. FASEB J, 2010, 24(12):4701-4710.
[18] NIEDERNBERG A, SCHERER C R, BUSCH A E, et al.Comparative analysis of human and rat S1P(5) (edg8): Differential expression profiles and sensitivities to antagonists[J]. Biochem Pharmacol, 2002, 64(8):1243-1250.
[19] JIMENEZ-URIBE A P, GOMEZ-SIERRA T, APARICIO-TREJO O E, et al. Backstage players of fibrosis: NOX4, mTOR, HDAC, and S1P; companions of TGF-beta[J]. Cell Signal, 2021,87:110123.
[20] 郑明克, 肖鹤, 黎燕, 等. 新型免疫抑制剂芬戈莫德的研究进展[J]. 国际药学研究杂志,2013,40(1):100-104.
[21] 陈本川. 治疗多发性硬化症新药——西尼莫德(siponimod)[J]. 医药导报,2019,38(9):1243-1253.
[22] KANTOR D, PHAM T, PATTERSON-LOMBA O, et al.Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis in the United States[J]. Neurol Ther, 2023, 12(3):849-861.
[23] DASH R P, RAIS R, SRINIVAS N R.Ponesimod, a selective sphingosine 1-phosphate (S1P1) receptor modulator for autoimmune diseases: Review of clinical pharmacokinetics and drug disposition[J]. Xenobiotica, 2018, 48(5):442-451.
[24] XUE M, YONG V W.Neuroinflammation in intracerebral haemorrhage: Immunotherapies with potential for translation[J]. Lancet Neurol, 2020,19(12):1023-1032.
[25] GENTILE A, MUSELLA A, BULLITTA S, et al.Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis[J]. J Neuroinflammation, 2016, 13(1):207.
[26] TRAN J Q, HARTUNG J P, PEACH R J, et al.Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator[J]. J Clin Pharmacol, 2017, 57(8):988-996.
[27] VACLAVKOVA A, CHIMENTI S, ARENBERGER P, et al.Oral ponesimod in patients with chronic plaque psoriasis: A randomised, double-blind, placebo-controlled phase 2 trial[J]. Lancet, 2014, 384(9959):2036-2045.
[28] OLSSON T, BARCELLOS L F, ALFREDSSON L.Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis[J]. Nat Rev Neurol, 2017,13(1):25-36.
[29] 黄燕, 王承德, 陈伟, 等. 类风湿性关节炎诊疗指南[J]. 中国中医药现代远程教育,2011,9(11):150-151.
[30] TAKESHITA H, KITANO M, IWASAKI T, et al.Sphingosine 1-phosphate (S1P)/S1P receptor 1 signaling regulates receptor activator of NF-kappaB ligand (RANKL) expression in rheumatoid arthritis[J]. Biochem Biophys Res Commun, 2012, 419(2):154-159.
[31] TANAKA K, HASHIZUME M, MIHARA M, et al.Anti-interleukin-6 receptor antibody prevents systemic bone mass loss via reducing the number of osteoclast precursors in bone marrow in a collagen-induced arthritis model[J]. Clin Exp Immunol, 2014, 175(2):172-180.
[32] LIU Y D, LIN H J, Li C Y, et al.Compound heterozygous mutations in the ALDH3A2 gene cause Sjogren-Larsson syndrome: A case report[J]. Int J Neurosci, 2020, 130(11):1156-1160.
[33] TIAN J, HUANG T, CHANG S, et al.Role of sphingosine-1-phosphate mediated signalling in systemic lupus erythematosus[J]. Prostaglandins Other Lipid Mediat, 2021, 156:106584.
[34] BOEHNCKE W H, SCHON M P.Psoriasis[J]. Lancet, 2015, 386(9997):983-994.
[35] TOKUYAMA M, MABUCHI T.New Treatment Addressing the Pathogenesis of Psoriasis[J]. Int J Mol Sci, 2020, 21(20):7488.
[36] MYSLIWIEC H, BARAN A, HARASIM-SYMBOR E, et al.Increase in circulating sphingosine-1-phosphate and decrease in ceramide levels in psoriatic patients[J]. Arch Dermatol Res, 2017,309(2):79-86.
[37] 中国特应性皮炎诊疗指南(2014版)[J]. 全科医学临床与教育, 2014,12(6):603-606.
[38] DE BENEDETTO A, RAFAELS N M, McGIRT L Y, et al. Tight junction defects in patients with atopic dermatitis[J]. J Allergy Clin Immunol, 2011,127(3):773-786.
[39] SAKAI T, HERRMANN N, MAINTZ L, et al.Serum sphingosine-1-phosphate is elevated in atopic dermatitis and associated with severity[J]. Allergy, 2021, 76(8):2592-2595.
[40] REINES I, KIETZMANN M, MISCHKE R, et al.Topical application of sphingosine-1-phosphate and FTY720 attenuate allergic contact dermatitis reaction through inhibition of dendritic cell migration[J]. J Invest Dermatol, 2009, 129(8):1954-1962.
[41] IGAWA S, OHZONO A, PHAM P, et al.Sphingosine 1-Phosphate Receptor 2 Is Central to Maintaining Epidermal Barrier Homeostasis[J]. J Invest Dermatol, 2021, 141(5):1188-1197.
[42] PARK S J, IM D S.Blockage of sphingosine-1-phosphate receptor 2 attenuates 2,4-dinitrochlorobenzene-induced atopic dermatitis in mice[J].Acta Pharmacol Sin, 2020,41(11):1487-1496.
[43] STERKENS A, LAMBERT J, BERVOETS A.Alopecia areata: a review on diagnosis, immunological etiopathogenesis and treatment options[J]. Clin Exp Med, 2021,21(2):215-230.
[44] 杨淑霞. 斑秃发病机制的研究进展[J]. 中国医学文摘(皮肤科学), 2016,33(4):465-470.
[45] 陈静, 张守民. 斑秃合并特应性皮炎免疫学特性及治疗研究进展[J]. 中国麻风皮肤病杂志, 2022,38(5):343-346.
[46] RAMÍREZ-MARÍN H A, TOSTI A. Emerging drugs for the treatment of alopecia areata[J]. Expert opinion on emerging drugs, 2022,27(4):379-387.